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Background: Osteoporosis is a highly heritable trait. Among the genes associated with bone mineral density
(BMD), the low-density lipoprotein receptor-related protein 5 gene (LRP5) has been consistently identified in
Caucasians. However LRP5 contribution to osteoporosis in populations of other ethnicities remains poorly known.
Methods: To determine whether LRP5 polymorphisms Ala1330Val and Val667Met are associated with BMD in North
Africans, these genotypes were analyzed in 566 post-menopausal Tunisian women with mean age of 59.5 ± 7.7 years,
of which 59.1% have low bone mass (T-score < −1 at spine or hip).
Results: In post-menopausal Tunisian women, 1330Val was weakly associated with reduced BMD T-score at lumbar
spine (p = 0.047) but not femur neck. Moreover, the TT/TC genotypes tended to be more frequent in women with
osteopenia and osteoporosis than in women with normal BMD (p = 0.066). Adjusting for body size and other
potential confounders, LRP5 genotypes were no longer significantly associated with aBMD at any site.
Conclusions: The less common Val667Met polymorphism showed no association with osteoporosis. The
Ala1330Val polymorphism is weakly associated with lower lumbar spine bone density and osteopenia/osteoporosis
in postmenopausal Tunisian women. These observations expand our knowledge about the contribution of LRP5
genetic variation to osteoporosis risk in populations of diverse ethnic origin.
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Osteoporosis is characterized by low bone mineral dens-
ity (BMD) and micro architecture deterioration of bone
tissue, leading to an increased risk of fractures that
occur mostly at the hip, spine and wrist [1]. It is increas-
ingly becoming a serious public-health issue because of
the morbidity and mortality associated with the disease
[2]. Hence, the identification and the management of
women at highest risk of osteoporosis is a main concern.
Bone mineral density (BMD) is a primary predictor of
osteoporotic fracture [3], and is used as a surrogate
definition of osteoporosis [4]. BMD changes with age,
peak levels being reached between the age of 20 and 30* Correspondence: sasrim2006@yahoo.com
1Osteoporosis and Arthritis laboratory, Rabta hospital, Faculty of Medicine of
Tunis, Tunis EL Manar University, Tunis, Tunisia
3Genetics, immunology and human pathologies Laboratory, Faculty of
Mathematical, Physical and Natural Sciences of Tunis, Tunis EL Manar
University, Tunis, Tunisia
Full list of author information is available at the end of the article
© 2014 Sassi et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orand then decreasing during the later decades of life [5].
The bone mass acquired by adulthood varies from one
population to another and is determined, essentially,
genetically. In fact, genetic factors account for 50% to
80% of the interindividual variations in bone mineral
density (BMD) [6-8].
To date, many genome-wide association studies (GWAS)
were performed and multiple genes were identified to be
associated with BMD and/or fragility fractures, including
the low-density lipoprotein receptor-related protein 5
(LRP5) gene and other genes in the Wnt signalling path-
way [9], like CTNNB1, and several genes in the RANKL/
RANK signalling pathway, such as TNFRSF11A [10,11].
The Wnt signaling pathway has been shown to be related
to bone mass and metabolism [12,13]. In osteoblasts,
LRP5 can transduce canonical signals to promote renewal
of stem cells, stimulation of pre-osteoblast replication, in-
duction of osteoblastogenesis, and inhibition of osteoblast
and osteocyte apoptosis by increasing the levels of ß-d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Characteristics of the studied Tunisian post
menopausal women
Variable Mean ± SD n
Age (yr) 59.5 ± 7.7
weight (kg) 72.0 ± 12.7
BMI 28.9 ± 5.0
Age at menarche (yr) 12.8 ± 1.6
Age at menopause (yr) 48.4 ± 4.5
Parity 3.4 ± 2.0
Fracture 55
No fracture 511
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transcription factors [14]. It is known that LRP5 is essen-
tial for normal morphology, development processes,
mechano-sensation and formation of bone [15]. Mapped
on chromosome 11q12–14, activating mutations in the
LRP5 gene are responsible for rare conditions with a “high
bone mass phenotype” [13,16] as well as autosomal dom-
inant osteopetrosis type 1 [17]. Conversely, inactivating
mutations are responsible for the osteoporosis pseudo-
glioma syndrome [12]. In addition to these mutations, a
number of polymorphisms were described in the LRP5
gene (http://www.ncbi.nlm.nih.gov/SNP). One of these,
the Ala1330Val (rs3736228, exon 18) polymorphism, was
associated with attenuated bone gain in prepubertal boys
[18], decreased BMD in Japanese [19], American [20],
Australian [21], and Dutch populations [22]. It was also
associated with an increased risk of fragility fractures in
postmenopausal Australian women [21] and in elderly
Dutch men [22]. Similarly, the Val667Met (rs4988321,
exon 9) polymorphism was associated with attenuated
bone gain in prepubertal boys but not in girls participating
in a 1-year longitudinal study [18]. In the same study, this
polymorphism was also associated with decreased lumbar
spine bone mineral content and projected bone area and
there was a trend toward lower BMD in the spine [18].
The implication of Ala1330Val and Val667Met polymor-
phisms in BMD variation and risk of post-menopausal
osteoporosis may differ between populations of various
origins. However in North Africa, no association study
was reported. To investigate whether allelic variations
of the LRP5 gene contribute to bone mass and osteopor-
osis in Tunisian population, we studied the association
of Ala1330Val and Val667Met polymorphisms with




Five hundred and sixty six postmenopausal Tunisian
women, all with Tunisian ancestry, were recruited for
osteoporosis consultation from the Rabta and Charles
Nicolles Hospitals of Tunis. Women were prospectively
recruited and included in the study regardless of their
BMD values. Subjects with a history of bone disease,
metabolic or endocrine diseases, hormone replacement
therapy, and a corticotherpeutical history were excluded.
Our study was approved by the National ethic committee
and all participants provided written informed consent.
Clinical measurements
The BMD was measured for the lumbar spine (L2-L4)
and femoral neck (dual femur) by dual energy X-ray
absorptiometry (DXA) using a GE-Lunar PRODIGYTM
device.The prevalence of clinical fractures was estimated by
obtaining a fracture history for each subject including
the age at the time of fracture, the site of fracture and
the trauma intensity. Only fractures caused by low im-
pact were included. All the characteristics of the studied
population as age, anthropometric and obstetric parame-
ters are shown in Table 1. The osteodensitometric results
of our population are summarized in Table 2 and the
classification of osteopenian and osteoporosis women
were made according to T-SCORE < −1, respectively <2.5
at spine or hip.
SNP genotyping
Genomic DNA was extracted from blood by Phenol
Chloroform procedure. Ala1330Val and Val667Met SNPs
were genotyped by the pyrosequencing method, consisting
of a series of four enzymatic steps resulting in sequencing
a short region that include the SNP [23]. The specific
primers used in the PCR are reported by Ferrari et al.
study [18].
Statistical analysis
Hardy-Weinberg equilibrium was tested for each SNP
by use of the standard χ2 test. Data are represented as
means ± SD. The categorical variables were compared
between genotypes using the χ2 test. The associations
between polymorphisms and BMD were assessed using
Student t test. Due to the extremely low frequency (<10%)
of the minor alleles, all analysis were performed under the
assumption of a dominant model (combining homozygote
for the minor allele and heterozygote in one group). Logis-
tic regression models were applied, after controlling for
several potential covariates (age, weight, height, meno-
pause age, menarche age, parity and fractures). Associ-
ation study and logistic regression were examined by SPSS
software.
Results
Our study comprised 566 Tunisian post-menopausal
women with a mean age of 59.5 ± 7.7 years (Table 1).
Table 2 Mean BMD by WHO diagnostic group
Mean ± SD
Variable Osteoporotic Osteopenic Normal
n = 141 n = 194 n = 231
LS BMD (g/cm2) 0.695 ± 0.065 0.827 ± 0.070 0.997 ± 0.092
RFN BMD (g/cm2) 0.769 ± 0.103 0.843 ± 0.096 0.971 ± 0.101
LFN BMD (g/cm2) 0.775 ± 0.096 0.837 ± 0.092 0.966 ± 0.113
LS, lumbar spine, RFN, right femur neck, LFN, left femur neck.
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osteopenic (Table 2). Among them, 55 women had a his-
tory of low trauma after the age of 45 years (Table 1).
Val667Met is a G/A substitution in exon 9, with geno-
type frequencies GG: 88.0%, GA: 11.7%, and AA: 0.4%.
Ala1330Val is a C/T substitution in exon18 with geno-
type frequencies CC: 79.9%, CT: 18.9%, and TT: 1.2%.
The genotype frequencies of the 2 SNPs, studied in our
population, did not significantly deviate from hardy
Weinberg equilibrium (χ2 = 0.54 and 0.88 respectively
for Val667Met and Ala1330Val). Association analysis are
summarized in Table 3. A significant difference in LS
BMD T-scores was found between CC and TC/TT geno-
types at spine (p = 0.047), but not at hip. Moreover, the
TT/TC genotypes tended to be more frequent in women
with osteopenia and osteoporosis than in normal womenTable 3 Association of LRP5 genotypes with BMDa
Polymorp
Val667Met
GG GA + AA
Parameter n = 498 n = 68
Osteopeniac 87.5 12.5
+osteoporosis (%)d
Normals (%) 88.7 11.3
fractured women (%) 89.1 10.9
Non fractured women (%) 87.9 12.1
BMD spine (g/cm2) 0.869 ± 0.144 0.854 ± 0.134
Tscore spine −1.085 ± 1.339 −1.327 ± 1.305
BMD right hip (g/cm2) 0.880 ± 0.127 0.872 ± 0.136
Tscore right hip −0.451 ± 1.066 −0.648 ± 1.225
BMD left hip (g/cm2) 0.877 ± 0.129 0.870 ± 0.127
Tscore right hip −0.514 ± 1.019 −0.635 ± 1.131
BMD total hip 0.857 ± 0.120 0.851 ± 0.132
Tscore total hip −0.652 ± 1.001 −0.801 ± 1.182
aContinuous variables (BMD values) are expressed as mean standard deviation, and
fracture) are expressed as percentages (%).
bBased on Student t test for continuous variables.
cWorld Health Organization definition: 1 standard deviatio ≥ T score ≤ 2.5 standard d
dWorld Health Organization definition: T score ≤ 2.5 standard deviation (29).
eBased on χ2 test between two groups OP + O and Normales.
fBased on χ2 test between two groups fractured and non fractured women.
*p≤ 0,05 significant in bold character.(p = 0.066) (Table 3). In contrast, the Val667Met geno-
types were not associated with aBMD and their distribu-
tion was similar between normal and osteoporotic/
osteopenic women. Distribution of LRP5 genotypes did
not differ between women with and without fragility
fractures (Table 3).
To further evaluate the independent contribution of
LRP5 polymorphisms to BMD in our population, we per-
formed a logistic regression analysis including age, weight,
age at menarche, age at menopause, parity, fractures and
LRP5 genotypes. As shown in Table 4, Age (p = 0.001) and
weight (p = 0.0001), were the most significant contributors
to BMD, followed by a non-significant contribution of
parity (p = 0.073), and A1330Val genotypes (p = 0.11).Discussion
For Tunisian women, a lumbar and femoral BMD ana-
lysis showed that their average values are close to those
of the Asian and Caucasian women. At femoral neck,
the lowest values were noted in European population.
The osteoporosis prevalence was higher in Asian than
in Tunisian and Caucasian population [24]. The dif-
ferences observed between various populations can be
caused by many environmental factors such as diet,
physical activity, smoking alcohol and the geographicalhisms
Ala1330Val
P CC CT + TT P
valueb, e, F n = 452 n = 114 valueb
77.6 22.4
0.373 83.1 16.9 0.066
85.5 14.5
0.499 79.3 20.7 0.182
0.438 0.873 ± 0.145 0.841 ± 0.134 0.072
0.170 −1.044 ± 1.338 −1.388 ± 1.297 0.047*
0.62 0.882 ± 0.127 0.867 ± 0.131 0.359
0.176 −0.433 ± 1.060 −0.639 ± 1.183 0.164
0.685 0.879 ± 0.129 0.865 ± 0.127 0.448
0.380 −0.499 ± 0.999 −0.645 ± 1.155 0.350
0.823 0.859 ± 0.120 0.847 ± 0.126 0.430
0.522 −0.635 ± 0.994 −0.807 ± 1.135 0.232
categorical variables (osteopenia, osteoporosis, presence osteoporotical
eviation (29).
Table 4 Logistic regression analysis of spine
Variable B t P value
Age (yr) −0.003 −3.471 0.001*
Weight (kg) 0.005 4.522 0.000
Age at menarche (yr) −0.005 −1.71 0.942
Age at menopause (yr) −0.002 −1.197 0.232
Parity 0.005 1.798 0.073
Fracture −0.026 −1.333 0.183
Ala1330Val genotype 0.032 1.57 0.117
*p≤ 0,05 significant in bold character.
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ism may also contribute to those differences.
During the past two decades, it has become clear that
many genes contribute to the variation in BMD in the
general population; however, candidate gene associ-
ation studies have led to conflicting and contradictory
findings [25]. Nevertheless, there is clear evidence for
the association between genetic variation of LRP5 and
BMD in the general Caucasian and Chinese populations
[18,19,21,26-30]. In African and North African popula-
tions, no information seems to be available about LRP5
and BMD variation.
In our Tunisian post-menopausal women, LRP5 poly-
morphisms frequencies were similar with previous stud-
ies reported in women with Caucasian background
[22,31,32], but different from those observed in Asian
population [19]. It should be noted that the association
of the Ala1330Val variant with BMD and osteoporosis/
osteopenia was in the same direction and had similar ef-
fect sizes in our study as in Europeans and Asians. How-
ever the absence of an association between BMD and
the Val667Met variant in our population was distinct
from previously consistent associations in other ethnic
groups. This difference could represent a truly different
genetic determination of osteoporosis risk between eth-
nicities or be due to a false negative result in our limited
sample of Tunisian women, considering that the A allele
is quite rare (6.1% < 10%).
Based on the physiological role of LRP5 in bone biology,
Val667Met and Ala1330Val should, in principle, result
in decreased Wnt signaling. Val667Met resides at the
top of the third propeller module in the extracellular
domain of the receptor, a domain that is thought to
interact with the Wnt-inhibitor Dkk1. Therefore, it is
possible that the Val667Met mutant may have a higher
binding affinity for Dkk1 as compared with the wild-
type protein [33]. Ala1330Val is located within the sec-
ond low-density lipoprotein (LDL) domain. Although
the exact molecular mechanism remains to be clarified,
the Ala1330Val mutant was shown to have a signicantly
reduced Wnt-signaling capacity as compared with thewild type molecule in two independent TCF-Lef re-
porter assays [31,34].
The Ala1330Val seemed to be associated with lower
spine bone density in post-menopausal Tunisian women.
In fact, the TT/TC genotype could be more frequent in
osteoporotic and osteopenic compared to women with
normal BMD (p = 0.066). However the effect of this vari-
ant was detected only at the lumbar spine and not at the
hip. Our results are concordant with those found in
Asian and Caucasian populations. Thus Bich et al. [25]
have demonstrated by a Bayesian meta-analysis that the
A1330V variant was mainly associated with lumbar spine
BMD in Asian populations, whereas in Caucasian popula-
tions associations occurred at both the lumbar spine and
femoral neck [25,35,36]. The association of A1330V with
lumbar spine than with femoral neck BMD is consistent
with recent genome-wide association studies [11] and
may reflect biological differences between the sites, a
lower heritability for the femoral neck site [37,38], or
higher measurement error at this site.
Richards et al. [11] noted that the LRP5 polymorphisms
were also significantly associated with fracture risk. But no
significant difference was found between fractured and
non-fractured women in our population. Considering the
small number of fractured women in our sample (n = 55),
our study is likely to be underpowered to detect such an
association.
The logistic regression analysis for all the parameters
including LRP5 genotypes reported a significant effect of
age and weight, while the association with Ala1330Val
genotypes was reduced. Since body size is strongly corre-
lated with bone size, and therefore aBMD, this observation
suggests that the association of LRP5 polymorphisms with
aBMD is at least partly mediated through LRP5 effects on
bone size. This hypothesis is further supported by a previ-
ous study in Swiss young boys and girls in whom LRP5
polymorphisms were associated with decreased lumbar
spine bone mineral content (BMC) and projected bone
area [18].Conclusions
In conclusions, the Ala1330Val variant seems to be weakly
associated with lower lumbar spine BMD in Tunisian
post-menopausal women, contributing to the notion
that LRP5 genetic variation is a ubiquitous determinant
of osteoporosis risk among various ethnicities. More in-
vestigation about the interaction of LRP5 polymorphisms
and other factors notably hormonal, environmental and
nutritional as well as physical activity are needed. These
latter factors obviously vary from one individual to the
next and from one population to the other, which can
further influence the contribution of LRP5 polymorphisms
to BMD in diverse ethnic groups.
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